Publications by authors named "Amy P Hack"
Article Synopsis
- Zalunfiban (RUC-4) is a new treatment aimed at quickly restoring blood flow in patients experiencing a heart attack (STEMI) by inhibiting a specific protein involved in blood clotting when given before a procedure to open blocked arteries.
- A study analyzed the effects of three doses of zalunfiban (0.075, 0.090, and 0.110 mg/kg) on 24 STEMI patients to see if higher doses led to better blood flow and reduced blood clot presence in the arteries during initial imaging.
- Results showed that higher doses of zalunfiban significantly improved blood flow measures and reduced the severity of blood clots, suggesting a clear dose-dependent
Objective: Prior research underlined the importance of timely oncological care as longer waiting times from diagnosis to treatment may result in poorer survival outcomes. The aim of this study was to determine the impact of waiting time from diagnosis to treatment on overall survival (OS) in patients with cervical cancer treated with curative intent.
Methods: Patients from a nationwide population-based cohort with newly diagnosed cervical cancer between 2010 and 2019 were studied.